Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248014 | 0.91 | CXCR2 (0.57) | CXCR2CXCR1CCR6 | |
| SCHEMBL245507 | 0.85 | CXCR2 (0.68) | CXCR2CXCR1CCR6 | |
| SCHEMBL12260603 | 0.80 | CXCR2 (0.61) | CXCR2CXCR1CCR6 | |
| SCHEMBL20313443 | 0.79 | CXCR2 (0.57) | CXCR2CXCR1CCR6 | |
| SCHEMBL3790926 | 0.78 | CXCR2 (0.51) | CXCR2CXCR1CCR6 | |
| SCHEMBL3790925 | 0.78 | CXCR2 (0.51) | CXCR2CXCR1CCR6 | |
| SCHEMBL13406925 | 0.78 | KCNA5 (0.38) | CXCR2CXCR1 | |
| SCHEMBL19351864 | 0.75 | CXCR2 (0.61) | CXCR2CXCR1CCR6 | |
| SCHEMBL20452291 | 0.75 | CXCR2 (0.61) | CXCR2CXCR1CCR6 | |
| SCHEMBL30515698 | 0.75 | CXCR2 (0.61) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | AQP3, SUCNR1, AQP1 | CXCR2 3127/4885CXCR1 1617/4885CCR6 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.